Biwei Yang

Shanghai, 200040, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Qiliqiangxin capsule attenuates platelet activation and thrombosis by suppressing Ca2+ influx and PKC signaling.

Qiliqiangxin capsule attenuates platelet activation and thrombosis by suppressing Ca2+ influx and PKC signaling.

Journal: Thrombosis journal

Published: October 19, 2025

SGMS2+ macrophages enhance NR4A3hi NK cell infiltration to improve prognosis and PD-1 treatment efficacy in hepatocellular carcinoma.

SGMS2+ macrophages enhance NR4A3hi NK cell infiltration to improve prognosis and PD-1 treatment efficacy in hepatocellular carcinoma.

Journal: Journal of translational medicine

Published: February 22, 2025

Comparison analysis of different doses bevacizumab plus ICIs and interventional therapy in unresectable hepatocellular carcinoma: a real-world study.

Comparison analysis of different doses bevacizumab plus ICIs and interventional therapy in unresectable hepatocellular carcinoma: a real-world study.

Journal: Journal of gastrointestinal oncology

Published: December 10, 2024

Survival in patients with unresectable hepatocellular carcinoma: TCC cocktail plus TACE vs TACE alone prospective randomized clinical trial.

Survival in patients with unresectable hepatocellular carcinoma: TCC cocktail plus TACE vs TACE alone prospective randomized clinical trial.

Journal: Journal of translational medicine

Published: December 05, 2024

Gelation embolism agents suppress clinical TACE-incited pro-metastatic microenvironment against hepatocellular carcinoma progression.

Gelation embolism agents suppress clinical TACE-incited pro-metastatic microenvironment against hepatocellular carcinoma progression.

Journal: EBioMedicine

Published: April 09, 2024

Successful treatment of tumor lysis syndrome associated with hepatic artery infusion chemotherapy in a patient with hepatocellular carcinoma: a case report.

Successful treatment of tumor lysis syndrome associated with hepatic artery infusion chemotherapy in a patient with hepatocellular carcinoma: a case report.

Journal: Journal of medical case reports

Published: March 13, 2024

Sulfiredoxin-1 promotes the growth of hepatocellular carcinoma by inhibiting TFEB-mediated autophagy and lysosome biogenesis.

Sulfiredoxin-1 promotes the growth of hepatocellular carcinoma by inhibiting TFEB-mediated autophagy and lysosome biogenesis.

Journal: Experimental cell research

Published: November 02, 2023

Identification of SGMS2 as a molecule involved in natural killer cell recruitment and its in-deep analysis in the liver cancer microenvironment: Evidence from large populations cohort.

Identification of SGMS2 as a molecule involved in natural killer cell recruitment and its in-deep analysis in the liver cancer microenvironment: Evidence from large populations cohort.

Journal: The journal of gene medicine

Published: June 25, 2023

Comprehensive Metabolic Profiling and Genome-wide Analysis Reveal Therapeutic Modalities for Hepatocellular Carcinoma.

Comprehensive Metabolic Profiling and Genome-wide Analysis Reveal Therapeutic Modalities for Hepatocellular Carcinoma.

Journal: Research (Washington, D.C.)

Published: November 19, 2022

Modeling cross-talk of RNA modification enzymes reveals tumor microenvironment-associated clinical significance and immunotherapy prediction in hepatobiliary malignancy.

Modeling cross-talk of RNA modification enzymes reveals tumor microenvironment-associated clinical significance and immunotherapy prediction in hepatobiliary malignancy.

Journal: MedComm

Published: September 17, 2022

Serum LAG-3 Predicts Outcome and Treatment Response in Hepatocellular Carcinoma Patients With Transarterial Chemoembolization.

Serum LAG-3 Predicts Outcome and Treatment Response in Hepatocellular Carcinoma Patients With Transarterial Chemoembolization.

Journal: Frontiers in immunology

Published: August 07, 2021

The E3 ubiquitin ligase SOCS-7 reverses immunosuppression via Shc1 signaling in hepatocellular carcinoma.

The E3 ubiquitin ligase SOCS-7 reverses immunosuppression via Shc1 signaling in hepatocellular carcinoma.

Journal: Laboratory investigation; a journal of technical methods and pathology

Published: August 02, 2021

Showing 1-12 of 36

Last Updated: 09/26/2026